… Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use
in preventing severe respiratory syncytial virus (RSV) infections in high-risk infants, children …

… for preventing respiratory syncytial virus (RSV) infection in high-risk infants. Respiratory
Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) is a polyclonal hyperimmune globulin …

… In December 2003 revised guidelines were issued by the AAP to delineate further … syncytial
virus immune globulin intravenous for the prevention of respiratory syncytial virus infections…

… intravenous immune globulin are licensed by the US Food … prevention of severe lower
respiratory tract infections caused by … 2003 AAP guidelines identify infants with congenital airway …

… As compared with the previous 2003 statement (2), the most important modifications are the
recommendations for prophylaxis in infants born between 32 weeks 0 days and 34 weeks 6 …

… RSV disease and outcomes, but studies of new medications … using respiratory syncytial virus
immune globulin prophylaxis… be administered palivizumab to prevent RSV infections;63,64 …

… phase II–IV trials and is available for use within internationally … the use of palivizumab in
patients with congenital heart disease… to RSV infection because of lower serum immune globulin …

… Among subjects receiving palivizumab during the 2002 to 2003 and 2003 to … Revised
indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous …

… The potential benefit of new strategies for prevention and treatment of RSV … dysplasia
using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group1997…

… use of passive immunization with palivizumab, the only licensed product available for prevention
of RSV lower respiratory tract disease … used hyperimmune polyclonal RSV intravenous …